You are here: Industry Insights > Dapagliflozin

News List

Glenmark gets tentative USFDA approval for generic anti-diabetes tablets expresspharma
April 29, 2020
The approval is for the strength of 10 mg/5 mg tablets of Dapagliflozin and Saxagliptin.
Dapagliflozin Lowers Risk for Worsening Heart Failure drugs
September 24, 2019
For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes ...
Study Shows Dapagliflozin Reduces Kidney Disease Progression, Renal Death in T2D Patients americanpharmaceuticalreview
June 13, 2019
The first sub-analysis of renal data from the Dapagliflozin Effect on Cardiovascular Events Thrombolysis In Myocardial Infarction (DECLARE-TIMI 58) trial indicates that dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor ...
EU approves AZ' Forxiga for type I diabetes pharmatimes
March 27, 2019
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC) for type I diabetes.
AZ’ Farxiga shows CV benefit in diabetes patients pharmatimes
March 19, 2019
Trial data show that AstraZeneca’s Farxiga (dapagliflozin) cut the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type II diabetes who had a prior heart attack.
AstraZeneca Pharma inks distribution pact with Abbott for diabetes drug expressbpd
December 10, 2018
The company will promote and distribute Dapagliflozin under the brand name GLEDEPA

Previous page 1 2 Next page